Gut microbiota in prostate cancer, Spain, case-control
Case-control study of 57 fecal metagenome samples from adult prostate cancer patients in Spain, comparing those with metastatic disease on androgen receptor pathway inhibitor therapy to non-advanced controls. machine-written summary
57 samples · 57 runs · ES · Adult · 2025 · 2.59 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 285 sample values (collection date, country, latitude, location region, longitude) |
| ✓ Abstract / description | 57 sample values (health condition detail) |
| – Full text | no open-access full text linked |
| – Supplementary tables | no supplementary tables available (or none open access) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet · share metadata |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Non-antibiotic pharmaceutical given as the study intervention (metformin design observational_with_procedure · population other_cancer · Androgen receptor pathway inhibitor (ARPI) therapy for metastatic prostate cancer
“patients with MPCa receiving ARPIs therapy were studied” — bioproject.description (study level; per-sample arms are in the intervention column below)
Genera, mean relative abundance over 56 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 57 | 100% | ||||
| country | 57 | 100% | 57 | |||
| health_condition | 0 | 0% | ||||
| subject_id | 0 | 0% | ||||
| collection_date | 57 | 100% | 57 | |||
| detailed_location | 57 | 100% | ||||
| health_condition_detail | 57 | 100% | 57 | |||
| latitude | 57 | 100% | 57 | |||
| location_region | 57 | 100% | 57 | |||
| longitude | 57 | 100% | 57 |
- Gut microbiota metabolic reprogramming in metastatic prostatic cancer: prognostic value in patients under androgen receptor pathway inhibitors therapy. 2025 own_data
Archive description
Metastatic prostate cancer (MPCa) is considered an aggressive condition. The objective was to elucidate the link between gut microbiota (GM) derived metabolites and disease progression in MPCa. Fecal microbiome shallow shotgun metagenomics of 15 patients with MPCa receiving ARPIs therapy were studied. A control group of 39 patients with non-advanced PCa was included. ARPIs-driven changes in the GM leading to functional redundancy in testosterone synthesis were observed. The GM could be contributing to epithelial–mesenchymal transition and MPCa progression by the increased synthesis of microbial-derived acetate. The feature-level analysis revealed that Bifidobacterium longum was enriched in the patients in a progression stage (LinDA coefficient 5.7) whereas Sutterella wadsworthensis, Butyricimonas, Bilophila wadsworthia, Alistipes indistinctus, Bacteroides thetaiotaomicron and Intestinimonas were depleted (LinDA coefficient -7.2, -5.1, -4.4, -3.9, -3.9 and -2.9, respectively). Bifidobacterium longum, Butyricimonas, Butyricimonas faecihominis, Bilophila sp. and Bacteroides thetaiotaomicron abundances were predictive of progression (AUC 0.88, 0.92, 0.88, 0.93 and 0.86, respectively, DESeq2 p < 0.00001). A deeper understanding of the multifaceted roles of intestinal microorganisms at various stages of the disease would be of crucial importance to achieve an overall perspective of the individual prognosis of MPCa.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by sonnet_x2 with confidence 0.75. Assay shotgun_dna.
- host study.description · “15 patients with MPCa receiving ARPIs therapy”
- body site study.title · “Gut microbiota signatures associated with advanced metastatic prostatic cancer”
- life stage study.description · “patients with MPCa receiving ARPIs therapy”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMEA118362808 | collection_date | 2022-01-24 | R1 | 0.90 | biosample.attribute:collection_date | 2022-01-24 |
| SAMEA118362808 | country | ES | R1 | 0.90 | sample.attr.geographic_location_country_and_or_sea | Spain |
| SAMEA118362808 | health_condition_detail | mixed_case_control: 15 MPCa patients on ARPI therapy vs 39 non-advanced PCa patients | R4 | 0.50 | study.description | 15 patients with MPCa receiving ARPIs therapy |
| SAMEA118362808 | latitude | 42.3220 | R1 | 0.90 | biosample.attribute:geographic_location_latitude+geographic_location_longitude | 42.322 -8.722 |
| SAMEA118362808 | location_region | Galicia | R1 | 0.60 | biosample.attribute:geographic_location_latitude+geographic_location_longitude | 42.322 -8.722 |
| SAMEA118362808 | longitude | -8.7220 | R1 | 0.90 | biosample.attribute:geographic_location_latitude+geographic_location_longitude | 42.322 -8.722 |
Sequencing
57 runs over 57 samples · mean 2.72 Gbp per run (median 2.59 Gbp, total 155.04 Gbp; 57 runs with a base count) · layout PAIRED 57 · platform ILLUMINA 57 · models NextSeq 1000 (57) · 98% of runs with a Sandpiper profile · first public 2025-12-15
Authors (0)
No author record.
Help complete this project
2 of the 4 core fields are below 50% coverage: health_condition, subject_id. Share metadata
Downloads
PRJEB84128.csv.gz (2.4 KB) · parquet (71.8 KB) — all 57 samples, every field with route and confidence · PRJEB84128_determinations.csv.gz (2.7 KB) — 342 evidence rows